BSEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BioStem Technologies, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.54−0.55 (-26.32%)
Close on Oct 19, 2026
- Market cap
- $26.68M
- P/E (TTM)
- –
- Dividend yield
- –
BioStem Technologies, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q2 25 | % of revenue | YoY |
|---|---|---|---|---|
| Hospital [Member] | $6.71M | $0 | 85.0% | – |
| Physician office [Member] | $1.10M | $10.96M | 13.9% | -90.0% |
| Other [Member] | $88.56K | $0 | 1.1% | – |
By region
From the segment and revenue-disaggregation notes of BioStem Technologies's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.